BioSpace News Archive

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it will make several presentations, including a Keynote Plenary presentation by Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, at the 5th Annual TPD Summit which is being held October 25‒28, 2022, in Boston, MA.

Biora Therapeutics, Inc today shared a poster presented at the Parenteral Drug Association (PDA) Universe of Pre-Filled Syringes and Injection Devices Conference.

Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends impacting one of the fastest-growing areas of specialty medicine.

Brand Institute is proud to announce its work with Celltrion Healthcare in developing the brand name VEGZELMA®, which was approved by the FDA on September 27, 2022.